NextPlat 10-Q Flags Going-Concern Doubt, Unremediated Material Weaknesses and Oscar Suspension
NXPL has more than doubled off its 52-week low of $3.375.
Summary
NextPlat's Q3 10-Q discloses going-concern doubt, unremediated material weaknesses and an Oscar Health claims suspension expected to cost about $0.3 million of revenue per month, alongside $10.5 million of quarterly revenue and $11.2 million of cash.
Key Events · Earnings and Guidance · NXPL
-
Going-Concern Doubt Disclosed
Recurring operating losses and negative operating cash flows raised substantial doubt about the ability to continue as a going concern for the twelve months following issuance; management says its plans, including the ATM Program, alleviate the doubt.
-
Material Weaknesses Remain Unremediated
The PBM performance bonus receivable and PIPE warrant modification valuation material weaknesses were still unremediated as of September 30, 2026, and disclosure controls and procedures were concluded not effective.
-
Oscar Suspension Hits Revenue
The October 30, 2026 adjudication suspension on Oscar Health claims at the Hallandale Beach pharmacy is expected to reduce revenue by approximately $0.3 million per month; Oscar claims were $2.3 million, or 7% of consolidated revenue, in the first nine months of 2026.
-
Q3 Revenue $10.5M, Loss Narrows
Third-quarter revenue fell to $10.5 million from $13.8 million a year earlier, but gross margin rose to 35% from 20% and the net loss narrowed to $0.7 million from $2.2 million.
Analysis · NXPL · Technology
The Q3 numbers were already public, but the full 10-Q carries three first-disclosed red flags. Management states that recurring operating losses and negative operating cash flows raised substantial doubt about the company's ability to continue as a going concern for the twelve months after issuance, and says its plans — including the ATM Program — alleviate that doubt. Separately, the PBM performance bonus receivable and PIPE warrant modification material weaknesses remained unremediated as of September 30, 2026, and disclosure controls were concluded not effective. On top of that, the October 30, 2026 Oscar Health adjudication suspension at the Hallandale Beach pharmacy is expected to cut revenue by roughly $0.3 million per month. Against $11.2 million of cash and only $3.8 million of remaining ATM capacity, the runway math is the thing that matters here.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXPL was trading at $6.94 on NASDAQ in the Technology sector, with a market capitalization of approximately $18.8M. The 52-week trading range was $3.38 to $9.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.